DK1659178T3 - Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein - Google Patents

Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein

Info

Publication number
DK1659178T3
DK1659178T3 DK06075362.1T DK06075362T DK1659178T3 DK 1659178 T3 DK1659178 T3 DK 1659178T3 DK 06075362 T DK06075362 T DK 06075362T DK 1659178 T3 DK1659178 T3 DK 1659178T3
Authority
DK
Denmark
Prior art keywords
purification
preparation
mage protein
mage
protein
Prior art date
Application number
DK06075362.1T
Other languages
English (en)
Inventor
Silva Teresa Cabezon
Joseph Cohen
Moncef Mohamed Slaoui
Bassols Carlota Vinals
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en
Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1659178T3 publication Critical patent/DK1659178T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK06075362.1T 1998-02-05 1999-02-02 Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein DK1659178T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
GBGB9802650.3A GB9802650D0 (en) 1998-02-06 1998-02-06 Vaccine
EP05076599A EP1584685B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination

Publications (1)

Publication Number Publication Date
DK1659178T3 true DK1659178T3 (da) 2010-07-12

Family

ID=26313069

Family Applications (4)

Application Number Title Priority Date Filing Date
DK99907476T DK1053325T3 (da) 1998-02-05 1999-02-02 Tumorassocierede antigenderivater fra mage-familien og nukleinsyresekvenser, der koder for dem, anvendt til fremstilling af fusionsproteiner og præparater til vaccination
DK06075362.1T DK1659178T3 (da) 1998-02-05 1999-02-02 Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
DK06075363.9T DK1659179T3 (da) 1998-02-05 1999-02-02 Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
DK05076599.9T DK1584685T3 (da) 1998-02-05 1999-02-02 Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK99907476T DK1053325T3 (da) 1998-02-05 1999-02-02 Tumorassocierede antigenderivater fra mage-familien og nukleinsyresekvenser, der koder for dem, anvendt til fremstilling af fusionsproteiner og præparater til vaccination

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK06075363.9T DK1659179T3 (da) 1998-02-05 1999-02-02 Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
DK05076599.9T DK1584685T3 (da) 1998-02-05 1999-02-02 Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination

Country Status (25)

Country Link
US (3) US8097257B2 (da)
EP (4) EP1659178B1 (da)
JP (2) JP4768121B2 (da)
KR (2) KR100633212B1 (da)
CN (1) CN1227360C (da)
AR (1) AR018064A1 (da)
AT (4) ATE462788T1 (da)
AU (1) AU737337B2 (da)
BR (1) BR9907691B1 (da)
CA (2) CA2584482C (da)
CY (4) CY1105685T1 (da)
CZ (2) CZ298364B6 (da)
DE (3) DE69929310T2 (da)
DK (4) DK1053325T3 (da)
ES (2) ES2342416T3 (da)
HU (1) HU228467B1 (da)
IL (4) IL137442A0 (da)
NO (2) NO328507B1 (da)
NZ (1) NZ506086A (da)
PT (4) PT1584685E (da)
SA (1) SA99200126B1 (da)
SI (4) SI1053325T1 (da)
TR (1) TR200002284T2 (da)
TW (1) TWI238853B (da)
WO (1) WO1999040188A2 (da)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
SI1117421T1 (en) * 1998-10-05 2004-12-31 Pharamexa A/S Methods for therapeutic vaccination
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
SI1650221T1 (sl) 2000-02-23 2012-09-28 Glaxosmithkline Biolog Sa Nove spojine
WO2001078777A2 (en) * 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
CA2411101C (en) * 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
PT2133100E (pt) 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
ATE534401T1 (de) * 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002364161A1 (en) 2001-12-12 2003-06-23 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
US20060257880A1 (en) * 2003-08-29 2006-11-16 The Nottingham Trent University Gastric and prostate cancer associated antigens
WO2005037190A2 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
CN101184504A (zh) 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
ATE515566T1 (de) * 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
ATE545708T1 (de) * 2005-11-14 2012-03-15 Univ Laval Krebsantigen mage-a9 und verwendungen davon
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5170976B2 (ja) 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
ES2539042T3 (es) 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
US20080187535A1 (en) 2007-01-15 2008-08-07 Normand Blais Vaccine
JP2010538996A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 単独またはＴｈｒ−Ｔｈｒ−Ｓｅｒ−Ｇｌｎ−Ｖａｌ−Ａｒｇ−Ｐｒｏ−Ａｒｇ−ＯＨのペプチドとの組合せにおけるＡｓｎ−Ａｓｐ−Ａｓｐ−Ｃｙｓ−Ｇｌｕ−Ｌｅｕ−Ｃｙｓ−Ｖａｌ−Ａｓｎ−Ｖａｌ−Ａｌａ−Ｃｙｓ−Ｔｈｒ−Ｇｌｙ−Ｃｙｓ−Ｌｅｕ−ＯＨのペプチドの治療剤としての使用
KR20100057063A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
NZ596545A (en) 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
HRP20120433T1 (en) * 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
AU2010252012A1 (en) 2009-05-27 2011-12-22 Glaxosmithkline Biologicals S.A. CASB7439 constructs
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
AU2012217723A1 (en) 2011-02-15 2013-08-29 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102251034B (zh) * 2011-07-05 2012-11-21 北京大学人民医院 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
EP2793938A4 (en) * 2011-12-22 2015-07-22 Glaxosmithkline Llc METHOD OF TREATING CANCER USING A MAGE-A3 IMMUNOTHERAPEUTIC PRODUCT COMPRISING A BRAF INHIBITOR AND / OR MEK INHIBITOR
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
CN105025884B (zh) 2013-03-01 2019-08-20 阿斯泰克斯制药公司 药物组合
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
KR102566134B1 (ko) 2015-12-07 2023-08-10 삼성전자주식회사 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
WO2017180420A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
EP3463300A1 (en) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
AU2019256536C1 (en) 2018-04-19 2026-01-15 Baylor College Of Medicine Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
AU2019386140B2 (en) 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
EP3886874B1 (en) 2018-11-29 2024-12-11 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
EP4136097A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
CA3217028A1 (en) 2021-04-22 2022-10-27 Baylor College Of Medicine Methods of engineering immune cells having reduced fratricidal activity
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es) 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) * 1988-08-31 1991-03-27 Smithkline Beecham Corp Vaccinal polypeptides
GB8824496D0 (en) 1988-10-19 1988-11-23 Beecham Group Plc Process
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001716A1 (en) 1990-07-23 1992-02-06 Zymogenetics, Inc. Protease resistant pdgf and methods of use
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5925729A (en) 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
DK0676964T3 (da) 1991-11-14 2001-02-05 Brigham & Womens Hospital Nitrosylering af enzym-SH-grupper som en terapeutisk modalitet
GB9213559D0 (en) * 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
WO1995004542A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE209690T1 (de) 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
EP0782453A1 (en) * 1994-09-30 1997-07-09 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0873350A4 (en) 1995-06-29 1999-06-30 Ludwig Inst Cancer Res ISOLATION OF A NUCLEIC ACID MOLECULE ENCODING SMAGE-3, A MURINE TUMOR REJECTION ANTIGEN PRECURSOR
AU7440196A (en) 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6030780A (en) 1996-10-15 2000-02-29 The Rockefeller University Purified Stat proteins and methods of purifying thereof
WO1998020165A2 (en) 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Biallelic markers
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US20020176865A1 (en) 1997-04-25 2002-11-28 Sophie Lucas Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
CA2324869A1 (en) 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Biallelic markers
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor

Also Published As

Publication number Publication date
SA99200126B1 (ar) 2006-08-20
AR018064A1 (es) 2001-10-31
SI1659178T1 (sl) 2010-07-30
HK1083026A1 (en) 2006-06-23
IL188875A (en) 2011-08-31
US20100204458A1 (en) 2010-08-12
HU228467B1 (en) 2013-03-28
EP1053325A2 (en) 2000-11-22
ATE315088T1 (de) 2006-02-15
CA2319309C (en) 2010-08-10
WO1999040188A2 (en) 1999-08-12
KR100633212B1 (ko) 2006-10-11
US20100209444A1 (en) 2010-08-19
US8597656B2 (en) 2013-12-03
NO20003958L (no) 2000-10-04
US8044183B2 (en) 2011-10-25
ATE513042T1 (de) 2011-07-15
CY1111831T1 (el) 2015-10-07
AU737337B2 (en) 2001-08-16
CA2584482A1 (en) 1999-08-12
PT1053325E (pt) 2006-05-31
CA2584482C (en) 2012-03-27
KR20010040675A (ko) 2001-05-15
IL188875A0 (en) 2009-02-11
DK1053325T3 (da) 2006-05-22
HUP0102639A1 (hu) 2001-11-28
CA2319309A1 (en) 1999-08-12
JP4768121B2 (ja) 2011-09-07
IL137442A (en) 2008-04-13
HUP0102639A3 (en) 2004-04-28
JP2002502604A (ja) 2002-01-29
WO1999040188A3 (en) 1999-10-14
EP1659178B1 (en) 2010-03-31
IL179010A0 (en) 2007-03-08
NO328507B1 (no) 2010-03-08
EP1053325B1 (en) 2006-01-04
SI1584685T1 (sl) 2011-07-29
PT1659179E (pt) 2011-09-16
DE69929310T2 (de) 2006-08-03
CZ298347B6 (cs) 2007-09-05
DE69942214D1 (de) 2010-05-12
CY1110180T1 (el) 2015-01-14
HK1093522A1 (en) 2007-03-02
DK1584685T3 (da) 2011-07-11
HK1093521A1 (en) 2007-03-02
PT1584685E (pt) 2011-06-17
EP1659178A3 (en) 2007-01-17
HK1033838A1 (en) 2001-09-28
US20120269835A1 (en) 2012-10-25
DE69943359D1 (de) 2011-05-26
NO20091665L (no) 2000-10-04
ATE505542T1 (de) 2011-04-15
DE69929310D1 (de) 2006-03-30
ES2255248T3 (es) 2006-06-16
PT1659178E (pt) 2010-06-28
BR9907691B1 (pt) 2011-05-31
EP1659178A2 (en) 2006-05-24
ES2342416T3 (es) 2010-07-06
EP1584685A2 (en) 2005-10-12
DK1659179T3 (da) 2011-10-10
PL342852A1 (en) 2001-07-16
JP2009201510A (ja) 2009-09-10
NO331719B1 (no) 2012-03-05
NZ506086A (en) 2003-01-31
KR100824105B1 (ko) 2008-04-21
CZ298364B6 (cs) 2007-09-05
TR200002284T2 (tr) 2000-11-21
EP1584685A3 (en) 2005-12-07
CY1111672T1 (el) 2015-10-07
IL137442A0 (en) 2001-07-24
US8097257B2 (en) 2012-01-17
CN1227360C (zh) 2005-11-16
CY1105685T1 (el) 2010-12-22
EP1659179A2 (en) 2006-05-24
KR20060067977A (ko) 2006-06-20
CN1295616A (zh) 2001-05-16
ATE462788T1 (de) 2010-04-15
EP1584685B1 (en) 2011-04-13
CZ20002869A3 (cs) 2001-01-17
AU2722099A (en) 1999-08-23
NO20003958D0 (no) 2000-08-04
BR9907691A (pt) 2000-11-14
TWI238853B (en) 2005-09-01
SI1053325T1 (sl) 2006-06-30
SI1659179T1 (sl) 2011-10-28
EP1659179A3 (en) 2007-01-17
EP1659179B1 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
DK1032566T5 (da) Fremgangsmåde til fremstilling af citalopram
DK1038008T3 (da) Fremgangsmåde til fremstilling af EGIII-lignende enzymer
NO994077D0 (no) Fremgangsmåte for fremstilling av keramiske membraner
DK0812845T3 (da) Fremgangsmåde til fremstilling af sildenafil
DK1123284T3 (da) Fremgangsmåde til fremstilling af citalopram
DK0770615T3 (da) Fremgangsmåde til fremstilling af dihalogenazolopyrimidiner
ATE256097T1 (de) Trennungsverfahren
ATE289577T1 (de) Trennungsverfahren
DK1053217T3 (da) Fremgangsmåde til fremstilling af n-propanol
DK1036179T4 (da) Fremgangsmåde til fremstilling af polypeptider med egnet glycosilering
DK0911416T3 (da) Fremgangsmåde til fremstilling af protein
DK0775100T3 (da) Fremgangsmåde til fremstilling af trifluorethylen
DK0937055T3 (da) Fremgangsmåde til fremstilling af d,I-alfa-tocopherol
DE69718835D1 (de) Verfahren zur Herstellung von (N-Phenylacetyl-N-2,6-xylyl)methyl Alaninat
IS2261B (is) Aðferð til framleiðslu á 5-sýanóþalíði
DK1027315T3 (da) Fremgangsmåde til fremstilling af n-butanol
DK0996642T3 (da) Fremgangsmåde til fremstilling af heparin
DK0756597T3 (da) Fremgangsmåde til fremstilling af puriner
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DE69833039D1 (de) Trennprozess
DK0946531T3 (da) Fremgangsmåde til fremstilling af thiazol-derivater
DK0912603T3 (da) Fremgangsmåde til fremstilling af visse azacyclohexapeptider
DE69918605D1 (de) Verfahren zur Herstellung von Kaliumoxonat
DK0973769T3 (da) Fremgangsmåde til fremstilling af eprosartan
DK0927766T3 (da) Enzymatisk fremgangsmåde til fremstilling af (S)-cyanhydriner